Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
CHAPEL HILL, N.C., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Bamboo Therapeutics, a biotechnology company focused on developing gene therapies for rare neurological diseases, announced today that it had acquired the viral gene therapy manufacturing facility (“Vector Core”) from the University of North Carolina (UNC) at Chapel Hill, N.C. Financial Details are not disclosed.
The Vector Core was founded in 1993 as a full-service viral vector production organization with extensive experience in vector design and process development, as well as manufacturing of research and clinical grade vectors. This 11,000 square foot facility has produced multiple research grade and clinical grade lots for pharmaceutical and biotechnology companies, as well as universities and foundations.
Bamboo has developed a proprietary suspension cell-based production platform that utilizes serum free/chemically defined media to increase scalability, efficiency and purity. Our proprietary system decreases the amount of processing steps necessary in methods using adherent cells, while also reducing the variability and shortcomings associated with using animal serum, giving Bamboo superior vector yields at a lower cost.
“We believe that having a leading manufacturing facility fully integrated into our business provides flexibility and a competitive advantage,” stated Dr. Jude Samulski, Scientific Founder and Chairman of Bamboo Therapeutics. “We anticipate rapidly moving our programs forward, including our DMD program, which is expected to enter the clinic in early 2017.”
About Bamboo Therapeutics, Inc.
Bamboo Therapeutics, Inc. is a fully integrated, clinical stage gene therapy company developing therapeutics to treat central nervous system and neuromuscular diseases. Bamboo combines its own in-house expertise in AAV gene therapy research, vector manufacturing, clinical development, and regulation of gene therapy products with collaborations with academic experts in rare neurologic disease areas of mutual interest. The company’s pipeline is focused on diseases of high unmet need, including giant axonal neuropathy (GAN), Canavan disease, Friedreich’s ataxia and Duchenne muscular dystrophy. Bamboo’s most advanced programs is for GAN, which is currently in a phase 1/2 trial.
Contact Richard E. T. Smith, PhD SVP, Corporate Communications and External Affairs [email protected]
